NCT02354612 2021-02-15
Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Tracon Pharmaceuticals Inc.
No longer available
Clinical Trials
13 trialsNCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT02560779 2020-07-17
Trial of TRC105 and Sorafenib in Patients With HCC
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT03181308 2020-06-24
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT01975519 2020-05-20
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT03780010 2019-10-28
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT02664961 2019-07-23
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Tracon Pharmaceuticals Inc.
Phase 2 Terminated
NCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT02396511 2019-06-11
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01326481 2019-03-18
TRC105
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT01381861 2019-03-05
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01332721 2018-12-05
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Tracon Pharmaceuticals Inc.
Phase 1 Completed